Table 3 Toxicity

From: Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial

 

Number of patients (%) with toxicities by WHO grades I, II, III and IV

 

I (%)

II (%)

III %)

IV (%)

Decrease in performance status

8 (23)

17 (49)

3 (9)

0

Fever

1 (3)

17 (49)

6 (17)

0

Diarrhoea

2 (6)

8 (23)

2 (6)

0

Nausea/vomiting

5 (14)

8 (23)

4 (11)

0

Local skin pain

0

2 (6)

0

0

General skin disorders

5 (14)

5 (14)

1 (3)

0

Hypotension

1 (3)

4 (11)

3 (9)

0

Mucositis

3 (9)

0

2 (6)

0

Cardiotoxicity

0

0

2 (6)

0

Neurological

0

1 (3)

0

0

Psychiatric

0

3 (9)

0

0

Infection

0

2 (6)

0

0

Weight gain

1 (3)

0

0

0

Haematological

5 (14)

4 (11)

2 (6)

0

Increase in transaminases

2 (6)

0

0

0

Hypercreatininaemia

2 (6)

0

0

0

Others

0

4 (11)

1 (3)

0